Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna-Maria Geretti

Showing results (151-160 of 176) with videos related to

Pageof 18
Sort By:
The Journal of Antimicrobial Chemotherapy|June 1, 2011
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort studyMattia C F Prosperi, Nicola Mackie, Simona Di Giambenedetto, et al.
JAMA|April 7, 2011
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysisJonathan Z Li, Roger Paredes, Heather J Ribaudo, et al.
The Journal of Infectious Diseases|April 10, 2004
A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipientsFrank M Mattes, Emma G Hainsworth, Anna-Maria Geretti, et al.
Antiviral Therapy|June 20, 2017
The association between detected drug resistance mutations and CD4<sup>+</sup> T-cell decline in HIV-positive individuals maintained on a failing treatment regimenAnna Schultze, Roger Paredes, Caroline Sabin, et al.
Plos One|April 25, 2013
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy responseJurgen Vercauteren, Gertjan Beheydt, Mattia Prosperi, et al.
AIDS (London, England)|March 15, 2005
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practiceAndrew N Phillips, David Dunn, Caroline Sabin, et al.
The Journal of Antimicrobial Chemotherapy|January 4, 2011
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatmentLinos Vandekerckhove, Chris Verhofstede, Els Demecheleer, et al.
The Lancet. Global Health|October 18, 2025
Causes, associated exposures, and outcomes of cirrhosis and hepatocellular carcinoma in Malawi: an observational cohort and case-control studyAlexander J Stockdale, Benno Kreuels, Isaac T Shawa, et al.
The Journal of Infectious Diseases|November 9, 2021
Hepatitis B Vaccination Impact and the Unmet Need for Antiviral Treatment in Blantyre, MalawiAlexander J Stockdale, James E Meiring, Isaac T Shawa, et al.
HIV Medicine|March 4, 2014
British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013Ed Wilkins, Mark Nelson, Kosh Agarwal, et al.
Pageof 18

Showing results (151-160 of 176) with videos related to

Sort By:
Pageof 18
The Journal of Antimicrobial Chemotherapy|June 1, 2011
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort studyMattia C F Prosperi, Nicola Mackie, Simona Di Giambenedetto, et al.
JAMA|April 7, 2011
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysisJonathan Z Li, Roger Paredes, Heather J Ribaudo, et al.
The Journal of Infectious Diseases|April 10, 2004
A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipientsFrank M Mattes, Emma G Hainsworth, Anna-Maria Geretti, et al.
Antiviral Therapy|June 20, 2017
The association between detected drug resistance mutations and CD4<sup>+</sup> T-cell decline in HIV-positive individuals maintained on a failing treatment regimenAnna Schultze, Roger Paredes, Caroline Sabin, et al.
Plos One|April 25, 2013
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy responseJurgen Vercauteren, Gertjan Beheydt, Mattia Prosperi, et al.
AIDS (London, England)|March 15, 2005
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practiceAndrew N Phillips, David Dunn, Caroline Sabin, et al.
The Journal of Antimicrobial Chemotherapy|January 4, 2011
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatmentLinos Vandekerckhove, Chris Verhofstede, Els Demecheleer, et al.
The Lancet. Global Health|October 18, 2025
Causes, associated exposures, and outcomes of cirrhosis and hepatocellular carcinoma in Malawi: an observational cohort and case-control studyAlexander J Stockdale, Benno Kreuels, Isaac T Shawa, et al.
The Journal of Infectious Diseases|November 9, 2021
Hepatitis B Vaccination Impact and the Unmet Need for Antiviral Treatment in Blantyre, MalawiAlexander J Stockdale, James E Meiring, Isaac T Shawa, et al.
HIV Medicine|March 4, 2014
British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013Ed Wilkins, Mark Nelson, Kosh Agarwal, et al.
Pageof 18